Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI vs UMEC vs salmeterol in COPD
NL-OMON45687Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Anoro Ellipta, umeclidinium and salmeterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in FEV1 at week 24. Started Jun 2017; status: active, not recruiting.
02
Drugs
Anoro Elliptaumeclidiniumsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON45687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45687.